Compare Illumina, Inc. (ILMN) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ProShares UltraPro Short QQQ ETF — how do they compare? Illumina, Inc. trades at $189.96 (market cap $27.94B), while ProShares UltraPro Short QQQ ETF trades at $40.22. The key difference: Illumina, Inc. is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | SQQQ | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.33 | $97.60 |
52-Week Low | $91.00 | $36.31 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
SQQQ trades at $42.68, down 0.26% with a bullish technical signal from moving averages but neutral oscillators. The ETF faces fundamental challenges as a leveraged short product with no traditional valuation metrics. Recent news highlights SQQQ's role as a tactical hedging tool against QQQ, though articles warn of significant long-term value erosion due to daily resets.
Outlook remains high-risk with SQQQ suitable only for sophisticated investors seeking short-term Nasdaq 100 downside protection. The primary risk is structural decay from daily rebalancing, making long-term holding detrimental. Analyst sentiment is cautious, emphasizing timing-dependent utility rather than investment merit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
